<?xml version="1.0" encoding="UTF-8"?>
<p>The use of LMWHs as anticoagulant therapy in COVID-19 infection is controversial at this time; the Chinese recommend the use of heparin (which also exerts an anti-inflammatory effect) as early anticoagulant treatment in severely ill patients in order to prevent disseminate intravascular coagulation and venous thrombosis, as signs of these disturbances were observed in pulmonary small vessels of critically ill COVID-19 patients (occlusion and microthrombosis), whereas the Japanese guidelines are against the use of heparin or heparin analogs in septic associated coagulopathy [
 <xref rid="B156-jcm-09-02084" ref-type="bibr">156</xref>].
</p>
